Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2023’, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever)
- The report reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ebolavirus Infections (Ebola Hemorrhagic Fever) therapeutics and enlists all their major and minor projects
- The report assesses Ebolavirus Infections (Ebola Hemorrhagic Fever) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Abivax SAAbVacc Inc
AIM ImmunoTech Inc
Albert B. Sabin Vaccine Institute Inc
Albert Einstein College of Medicine
AnGes Inc
ANP Technologies Inc
AntoXa Corp
Arisan Therapeutics Inc
Auro Vaccines LLC
Bharat Biotech Ltd
BioComo Inc
BioFactura Inc
Biotron Ltd
Bioxytran Inc
Celdara Medical LLC
Chicago Biosolutions Inc
Cocrystal Pharma Inc
Collaborations Pharmaceuticals Inc
Creative Biotherapeutics LLC
Dominari Holdings Inc
Drexel University
Dultech Advanced Sciences
Elixirgen Therapeutics Inc
Emergent BioSolutions Inc
Emergex Vaccines Holding Ltd
Fab’entech SA
Fibroplate Inc
Flow Pharma Inc
Fox Chase Chemical Diversity Center Inc
Galactica Biotech Ltd
Gamaleya Federal Research Center of Epidemiology and Microbiology
Georgia State University
GeoVax Labs Inc
Gilead Sciences Inc
Global BioLife Inc Ltd
H&P Labs Inc
Helleday Laboratory
ImmunityBio Inc
Imperial College London
Inovio Pharmaceuticals Inc
Integral Molecular Inc
Integrated BioTherapeutics Inc
IntelliStem Technologies Inc
International AIDS Vaccine Initiative Inc
Jawaharlal Nehru Centre for Advanced Scientific Research
Johnson & Johnson
Mapp Biopharmaceutical Inc
Maxwell Biosciences Inc
Merck & Co Inc
Microbiotix Inc
Micropharm Ltd
Moderna Inc
Nykode Therapeutics ASA
Oita University Institute of Advanced Medicine Inc
OncXerna Therapeutics Inc
Orgenesis Inc
Ostrich Pharma USA Inc
OyaGen Inc
Palisades Therapeutics
PanThera Biopharma LLC
Phelix Therapeutics LLC
Philipps University of Marburg
Phoenix Biotechnology Inc
Public Health Agency of Canada
Red Queen Therapeutics Inc
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Research Institute of Influenza
ReVacc Biotech
Riboscience LLC
Rodos BioTarget GmbH
SAB Biotherapeutics Inc
Secarna Pharmaceuticals GmbH & Co KG
Selva Therapeutics Inc
Sihuan Pharmaceutical Holdings Group Ltd
SK Bioscience Ltd
Soligenix Inc
Southwest Research Institute
TFF Pharmaceuticals Inc
The National Institute of Allergy and Infectious Diseases
Tiba Biotech LLC
U.S. Army Medical Research Institute of Infectious Diseases
University of Belgrade
University of Iowa
University of Nebraska
University of Oxford
University of Queensland
University of Tokyo
University of Virginia School of Medicine
University of Wisconsin Madison
Uvax Bio LLC
Vaxeal Holding SA
Veru Inc
Vir Biotechnology Inc
XBiotech Inc
Yaso Therapeutics Inc
Yisheng Biopharma Co Ltd
Zalgen Labs LLC
Zevra Therapeutics Inc